<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3032">
  <stage>Registered</stage>
  <submitdate>14/12/2010</submitdate>
  <approvaldate>14/12/2010</approvaldate>
  <nctid>NCT01263886</nctid>
  <trial_identification>
    <studytitle>Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer</studytitle>
    <scientifictitle>A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym>DISRUPT</trialacronym>
    <secondaryid>2010-019384-11</secondaryid>
    <secondaryid>EFC10259</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ombrabulin (AVE8062)
Treatment: drugs - placebo

Experimental: AVE8062 and combination - Day 1: AVE8062
Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin

Placebo Comparator: Placebo - Day 1: placebo
Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin


Treatment: drugs: ombrabulin (AVE8062)
Pharmaceutical form:solution
Route of administration: intravenous

Treatment: drugs: placebo
Pharmaceutical form:solution
Route of administration: intravenous

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression free survival (PFS)</outcome>
      <timepoint>approximately 1.5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS)</outcome>
      <timepoint>approximately 1.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate (OR)</outcome>
      <timepoint>approximately 1.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Histologically proven squamous metastatic non-small cell lung cancer (stage IV,
             according to Tumor Nodes Metastasis (TNM) classification seventh edition)

          -  Patients with measurable disease, Response Evaluation Criteria In Solid Tumors
             (RECIST) criteria (version 1.1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Prior chemotherapy, immunotherapy or targeted therapy for lung cancer disease
             (including adjuvant/neoadjuvant therapy)

          -  History of brain metastases, uncontrolled spinal cord compression, or carcinomatous
             meningitis

          -  History of another neoplasm. Adequately treated basal cell or squamous skin cancer, or
             in situ cervical cancer, or any other cancer from which the patient has been
             disease-free for &gt;5 years are allowed

          -  Participation in another clinical trial and any concurrent treatment with any
             investigational drug within 30 days prior to randomization

          -  Acquired immunodeficiency syndrome (AIDS-related illness) or known human
             immunodeficiency virus (HIV) disease requiring antiretroviral treatment

          -  Any severe acute or chronic medical condition, which could impair the ability of the
             patient to participate in the study or interfere with interpretation of study results

          -  Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to
             randomization

          -  Patient with reproductive potential (Male/Female) who do not agree to use accepted and
             effective method of contraception during the study treatment period and for at least 3
             months after the completion of the study treatment. The definition of "effective
             method of contraception" will be based on the investigator's judgment

          -  Inadequate organ function

          -  Pre-existing peripheral neuropathy &gt; grade 1 according to the National Cancer
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V.4.03

          -  Pre-existing hearing impairment &gt; grade 2

          -  Known hypersensitivity due to taxanes and /or polysorbate 80 or any other compound of
             the study drug combination

          -  Other serious illness or medical conditions such as (but not restricted): Active
             infection, Superior vena cava syndrome, Pericardial effusion requiring intervention
             (drainage)

          -  Documented medical history of myocardial infarction, documented angina pectoris,
             arrhythmia especially severe conduction disorder such as second or third-degree
             atrioventricular block, stroke, or history of arterial or venous thromboembolism
             within the past 6 months still requiring anticoagulants.

          -  Uncontrolled hypertension within 3 months prior to study treatment or patient with
             organ damage related to hypertension.

          -  Patient with Left Ventricular Ejection Fraction (LVEF) value lower than institution
             inferior normal limit, evaluated by echocardiography or angiocardiography

          -  12-lead Electrocardiogram (ECG): Infarction Q-wave, ST segment depression or elevation
             =1 mm in at least 2 contiguous leads

          -  History of gross hemoptysis (i.e. 1/2 teaspoon of red blood or more per episode)
             within the past 1 month.

          -  Has non-squamous NSCLC(adenocarcinoma/large cell or other)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>176</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Investigational Site Number 036002 - Bendigo</hospital>
    <hospital>Investigational Site Number 036001 - Southport</hospital>
    <postcode>3550 - Bendigo</postcode>
    <postcode>4215 - Southport</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Valparaiso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 02</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Herblain Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gauting</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gro√ühansdorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Immenhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Monza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Sremska Kamenica</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Sumy</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary Objective:

        -  To demonstrate progression free survival (PFS) improvement for ombrabulin compared to
           placebo, in combination with taxane and platinum, as first line treatment for patients
           with metastatic non-small cell lung cancer (NSCLC).

      Secondary Objective:

        -  To determine overall survival (OS), overall response rate (ORR) according to Response
           Evaluation Criteria In Solid Tumors (RECIST) criteria, safety, and evaluate potential
           biomarkers, pharmacokinetic (PK) analysis of ombrabulin and its main metabolite,
           RPR258063, using a population approach.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01263886</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Sciences &amp; Operations</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>